Novartis Korea highlights 바카라 배팅 법 benefits of 'COSENTYX' for ankylosing spondylitis at KCR 2025

[by Sung, Jae Jun] Novartis Korea announced on May 27 that it hosted a luncheon symposium highlighting the 바카라 배팅 법 value of 'COSENTYX (secukinumab)' during the 45th Korean College of Rheumatology Annual Scientific Meeting & the 19th International Symposium (KCR 2025), held on May 16. The symposium took place over three days, from May 15 to 17, at the Conrad Hotel in Seoul.

The symposium was moderated by Professor Park Yong-beom of Severance Hospital, with Professor Lianne S. Gensler of the University of California, San Francisco (UCSF) participating as the keynote speaker. Gensler delivered a presentation titled 'Secukinumab in Axial Spondyloarthritis.' She is a former chair of the North American Spondyloarthritis Research and Treatment Network (SPARTAN) and has also served as a member of the SPARTAN Guidelines Committee.

Gensler explained that COSENTYX demonstrates a strong therapeutic response in patients with ankylosing spondylitis by inhibiting 'Interleukin-17A (IL-17A).' She highlighted findings from the Phase 3 clinical trial (MEASURE 2), noting that patients without prior exposure to biologic agents exhibited a significantly higher 'ASAS20 response rate' at week 16 compared to those in the placebo group. She further emphasized that the treatment’s clinical benefit was sustained, as evidenced by continuous symptom improvement observed over a five-year follow-up period.

In addition, Gensler referenced the findings of the 'SURPASS' study, which demonstrated that both COSENTYX and adalimumab biosimilar treatment groups exhibited radiographic progression inhibition in high-risk patients with high levels of 'C-reactive protein (CRP),’ a key inflammatory indicator. Furthermore, the shared data from the real-world study 'FORSYA' reported that the one-year treatment retention rate was higher among patients who received COSENTYX as their first-line biologic therapy.

“Early diagnosis and prompt treatment are most important in the management of ankylosing spondylitis,” stated Professor Park Yong-beom, who served as chair of the symposium. “COSENTYX is demonstrating notable clinical value as a first-line treatment option in Korea.”

“The symposium served as a valuable opportunity for sharing the most recent clinical data on COSENTYX with leading Korean experts in rheumatology,” expressed Park Joo-young, head of Novartis Korea’s Immunology Therapeutic Area. “We will continue making our best effort to improve the quality of life of patients with axial spondylitis,” he added.